Amifostine trihydrate

Research use only, not for human use.

Amifostine is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin.

Amifostine is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin.

Amifostine (0.78125-100?μM, 24 h)trihydrate reduces tert-Butyl hydroperoxide (TBHP)-induced cell damage in a dose-dependent manner and significantly reduces H9c2 cells apoptosis at a concentration of 100 μM.

Amifostine (i.v., 400 mg/kg, 4 h) trihydrate has a protective effect against myocardial I/R injury in male C57BL/6 mice. Animal Model:Male C57BL/6 mice with myocardial I/R injury Dosage:400 mg/kg Administration: Intravenous injection; 4 hours Result:Attenuated cardiomyocyte apoptosis and reduced the production of I/R-induced ROS.Significantly reduced the expression of cleaved caspase 3 and Bax whileenhanced the expression of SOD1, SOD2 and Bcl2.Significantly increased SOD activity and reduced MDA levels.

——

Others

Other Targets

Others

Others-Field

——

112901-68-5

268.27

C5H15N2O3PS·3H2O

>98% (HPLC)

In Vitro:?H2O : 125 mg/mL (465.95 mM)

O.O.O.NCCCNCCSP(O)(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years